FRI0381 During antisynthetase syndrome, anti-citrullinated peptides are a marker of severe joint disease

Background The clinical meaning of anti-citrullinated peptide antibodies (ACPA) in antisynthetase syndrome (ASS) is unknown. Methods ASS patients with ACPA were identified among a 9 French center series of 284 patients with ASS and through declarative cases from clinicians registered on the Club Rhu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2013-06, Vol.72 (Suppl 3), p.A502-A502
Hauptverfasser: Meyer, A., Lefevre, G., Tournadre, A., Le Goff, B., Ottaviani, S., Buchdahl, A.-L., De Brandt, M., Coquerelle, P., Flipo, R.-M., Falgarone, G., Bernard, G., Amoura, Z., Benveniste, O., Sibilia, J., Hachulla, E., Hervier, B.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A502
container_issue Suppl 3
container_start_page A502
container_title Annals of the rheumatic diseases
container_volume 72
creator Meyer, A.
Lefevre, G.
Tournadre, A.
Le Goff, B.
Ottaviani, S.
Buchdahl, A.-L.
De Brandt, M.
Coquerelle, P.
Flipo, R.-M.
Falgarone, G.
Bernard, G.
Amoura, Z.
Benveniste, O.
Sibilia, J.
Hachulla, E.
Hervier, B.
description Background The clinical meaning of anti-citrullinated peptide antibodies (ACPA) in antisynthetase syndrome (ASS) is unknown. Methods ASS patients with ACPA were identified among a 9 French center series of 284 patients with ASS and through declarative cases from clinicians registered on the Club Rhumatismes et Inflammation web site. ASS was defined by the presence of an antisynthetase antibody (ARS) and at least two organ involvements among interstitial lung disease (ILD) (abnormal pulmonary function tests and/or typical thoracic HRCT-scan), myositis (muscle weakness, CK level >2 times normal range, myopathic changes on EMG and/or typical features on biopsy) and typical skin manifestations. ACPA were positive when >30 IU/ml (ELISA and/or LUMINEX). Results Eleven female and two male (median age of 43 years, range 23-57) were tested positive for ACPA (median serum amount 183 IU/ml, range 33-7742). ARS were anti-Jo1 (n=10), anti-PL7 (n=2) or anti-PL12 (n=1) and were identified concomitantly (n=10), 4 years before (n=1) or 3-6 years after (n=2) the ACPA detection. Rheumatoid factor (latex) was found in 11 patients (213 IU/L, range 16-925). Among the tested patients, HLA-DR4 allele was found in one case. All patient suffered of symetrical arthritis, involving mainly small joints of the hand (n=13) sparing distal interphalangeal (IP) joints (n=12), with 9 tender joints (range 4-24) and 5.5 swollen joints (range 2-18). The visual analogic pain scale was 60/100, ranging from 20 to 66. Bone erosions were found in 10 patients (78%), mainly on metacarpophalangeal (n=6), metatarsophalangeal (n=4), wirst (n=4) and proximal IP (n=3) joints. All patients presented with at least 2 other symptoms of ASS: - ILD (n=11), occurring prior to (n=3, 2-5 years), at the same time of (n=4) or after (n=4, 1-6 years) the detection of ACPA, with variable severity (vital capacity 94% (range 44-100) and DLCO 67 % (range 48-103). HRCT findings were systematically in accordance with non-specific interstitial pneumonia. - Myositis (n=11) was diagnosed 5-11 years before (n=3), concomitantly (n=5) and 1-3 years after (n=3) the ACPA detection. Muscle weakness was present in 10 patients and the median CK level was 1807 UI/L (range 245-11,434). - Skin manifestations (n=9) were mechanic’s hand (n=3), signs of dermatomyositis (n=4) and/or Raynaud’s phenomenon (n=7) that appeared 1- 2 years before (n=3), concomitantly (n=3) or 3 years after (n=1) the detection of ACPA. All patients received cortico
doi_str_mv 10.1136/annrheumdis-2013-eular.1508
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777912000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008739481</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1650-901895154dc72269b0f8bc721cb3fcccf04ac90ccba21c3b2de0c81b3260b1353</originalsourceid><addsrcrecordid>eNqVkMFO3DAQhq2qlbosfQdLXAmdiRMnESe0BUqFSkULSL1YtjMpTneTxXaqcuPSF-2T4GUR6rUnj3___4znY2wP4QBRyPd6GPwtTavWhSwHFBlNS-0PsIT6FZthIeskS3jNZgAgsqKR1Vu2E0KfrlBjPWP9yeUZiBr_Pvz5MHk3_OB6iC7cD_GWog7EU9n6cUX7Tw-ZddFPy6UbdKSWr2kdXUuBa09c85X2P8nzseOBflGS-tENkaffUWq1y950ehno3fM5Z1cnx98WH7Pzi9OzxdF5ZlCWkDWAdVNiWbS2ynPZGOhqk0q0RnTW2g4KbRuw1uikCZO3BLZGI3IJBkUp5mxv23ftx7uJQlT9OPkhjVRYVVWD-QbGnB1uXdaPIXjq1Nq7tMC9QlAbuOofuGoDVz3BVRu4KZ1t0y5E-v0STfsrWYmqVJ-vF-rrp8UXuCy-q5vkl1u_WfX_NegRy1OW1w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777912000</pqid></control><display><type>article</type><title>FRI0381 During antisynthetase syndrome, anti-citrullinated peptides are a marker of severe joint disease</title><source>BMJ Journals - NESLi2</source><creator>Meyer, A. ; Lefevre, G. ; Tournadre, A. ; Le Goff, B. ; Ottaviani, S. ; Buchdahl, A.-L. ; De Brandt, M. ; Coquerelle, P. ; Flipo, R.-M. ; Falgarone, G. ; Bernard, G. ; Amoura, Z. ; Benveniste, O. ; Sibilia, J. ; Hachulla, E. ; Hervier, B.</creator><creatorcontrib>Meyer, A. ; Lefevre, G. ; Tournadre, A. ; Le Goff, B. ; Ottaviani, S. ; Buchdahl, A.-L. ; De Brandt, M. ; Coquerelle, P. ; Flipo, R.-M. ; Falgarone, G. ; Bernard, G. ; Amoura, Z. ; Benveniste, O. ; Sibilia, J. ; Hachulla, E. ; Hervier, B.</creatorcontrib><description>Background The clinical meaning of anti-citrullinated peptide antibodies (ACPA) in antisynthetase syndrome (ASS) is unknown. Methods ASS patients with ACPA were identified among a 9 French center series of 284 patients with ASS and through declarative cases from clinicians registered on the Club Rhumatismes et Inflammation web site. ASS was defined by the presence of an antisynthetase antibody (ARS) and at least two organ involvements among interstitial lung disease (ILD) (abnormal pulmonary function tests and/or typical thoracic HRCT-scan), myositis (muscle weakness, CK level &gt;2 times normal range, myopathic changes on EMG and/or typical features on biopsy) and typical skin manifestations. ACPA were positive when &gt;30 IU/ml (ELISA and/or LUMINEX). Results Eleven female and two male (median age of 43 years, range 23-57) were tested positive for ACPA (median serum amount 183 IU/ml, range 33-7742). ARS were anti-Jo1 (n=10), anti-PL7 (n=2) or anti-PL12 (n=1) and were identified concomitantly (n=10), 4 years before (n=1) or 3-6 years after (n=2) the ACPA detection. Rheumatoid factor (latex) was found in 11 patients (213 IU/L, range 16-925). Among the tested patients, HLA-DR4 allele was found in one case. All patient suffered of symetrical arthritis, involving mainly small joints of the hand (n=13) sparing distal interphalangeal (IP) joints (n=12), with 9 tender joints (range 4-24) and 5.5 swollen joints (range 2-18). The visual analogic pain scale was 60/100, ranging from 20 to 66. Bone erosions were found in 10 patients (78%), mainly on metacarpophalangeal (n=6), metatarsophalangeal (n=4), wirst (n=4) and proximal IP (n=3) joints. All patients presented with at least 2 other symptoms of ASS: - ILD (n=11), occurring prior to (n=3, 2-5 years), at the same time of (n=4) or after (n=4, 1-6 years) the detection of ACPA, with variable severity (vital capacity 94% (range 44-100) and DLCO 67 % (range 48-103). HRCT findings were systematically in accordance with non-specific interstitial pneumonia. - Myositis (n=11) was diagnosed 5-11 years before (n=3), concomitantly (n=5) and 1-3 years after (n=3) the ACPA detection. Muscle weakness was present in 10 patients and the median CK level was 1807 UI/L (range 245-11,434). - Skin manifestations (n=9) were mechanic’s hand (n=3), signs of dermatomyositis (n=4) and/or Raynaud’s phenomenon (n=7) that appeared 1- 2 years before (n=3), concomitantly (n=3) or 3 years after (n=1) the detection of ACPA. All patients received corticosteroids while eleven were treated with DMARDs : methotrexate (n=11), leflunomid (n=1), plaquenil (n=1), mycophenolate mofetil (n=2), Azathioprine (n=1). Seven patients received biologics because of refractory arthritis, including rituximab (n=4), infliximab (n=3), adalimumab (n=1), etanercept (1), tocilizumab (n=1) and/or abatacept (n=1). Other treatments were intraveinous immunoglobulins (n=1) and cyclophosphamide (n=1). Conclusions In ASS, ACPA are associated with severe and erosive arthritis, whereas the prognosis of the other specific ASS involvements seems good. Disclosure of Interest: None Declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2013-eular.1508</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A502-A502</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A502.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A502.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids></links><search><creatorcontrib>Meyer, A.</creatorcontrib><creatorcontrib>Lefevre, G.</creatorcontrib><creatorcontrib>Tournadre, A.</creatorcontrib><creatorcontrib>Le Goff, B.</creatorcontrib><creatorcontrib>Ottaviani, S.</creatorcontrib><creatorcontrib>Buchdahl, A.-L.</creatorcontrib><creatorcontrib>De Brandt, M.</creatorcontrib><creatorcontrib>Coquerelle, P.</creatorcontrib><creatorcontrib>Flipo, R.-M.</creatorcontrib><creatorcontrib>Falgarone, G.</creatorcontrib><creatorcontrib>Bernard, G.</creatorcontrib><creatorcontrib>Amoura, Z.</creatorcontrib><creatorcontrib>Benveniste, O.</creatorcontrib><creatorcontrib>Sibilia, J.</creatorcontrib><creatorcontrib>Hachulla, E.</creatorcontrib><creatorcontrib>Hervier, B.</creatorcontrib><title>FRI0381 During antisynthetase syndrome, anti-citrullinated peptides are a marker of severe joint disease</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Background The clinical meaning of anti-citrullinated peptide antibodies (ACPA) in antisynthetase syndrome (ASS) is unknown. Methods ASS patients with ACPA were identified among a 9 French center series of 284 patients with ASS and through declarative cases from clinicians registered on the Club Rhumatismes et Inflammation web site. ASS was defined by the presence of an antisynthetase antibody (ARS) and at least two organ involvements among interstitial lung disease (ILD) (abnormal pulmonary function tests and/or typical thoracic HRCT-scan), myositis (muscle weakness, CK level &gt;2 times normal range, myopathic changes on EMG and/or typical features on biopsy) and typical skin manifestations. ACPA were positive when &gt;30 IU/ml (ELISA and/or LUMINEX). Results Eleven female and two male (median age of 43 years, range 23-57) were tested positive for ACPA (median serum amount 183 IU/ml, range 33-7742). ARS were anti-Jo1 (n=10), anti-PL7 (n=2) or anti-PL12 (n=1) and were identified concomitantly (n=10), 4 years before (n=1) or 3-6 years after (n=2) the ACPA detection. Rheumatoid factor (latex) was found in 11 patients (213 IU/L, range 16-925). Among the tested patients, HLA-DR4 allele was found in one case. All patient suffered of symetrical arthritis, involving mainly small joints of the hand (n=13) sparing distal interphalangeal (IP) joints (n=12), with 9 tender joints (range 4-24) and 5.5 swollen joints (range 2-18). The visual analogic pain scale was 60/100, ranging from 20 to 66. Bone erosions were found in 10 patients (78%), mainly on metacarpophalangeal (n=6), metatarsophalangeal (n=4), wirst (n=4) and proximal IP (n=3) joints. All patients presented with at least 2 other symptoms of ASS: - ILD (n=11), occurring prior to (n=3, 2-5 years), at the same time of (n=4) or after (n=4, 1-6 years) the detection of ACPA, with variable severity (vital capacity 94% (range 44-100) and DLCO 67 % (range 48-103). HRCT findings were systematically in accordance with non-specific interstitial pneumonia. - Myositis (n=11) was diagnosed 5-11 years before (n=3), concomitantly (n=5) and 1-3 years after (n=3) the ACPA detection. Muscle weakness was present in 10 patients and the median CK level was 1807 UI/L (range 245-11,434). - Skin manifestations (n=9) were mechanic’s hand (n=3), signs of dermatomyositis (n=4) and/or Raynaud’s phenomenon (n=7) that appeared 1- 2 years before (n=3), concomitantly (n=3) or 3 years after (n=1) the detection of ACPA. All patients received corticosteroids while eleven were treated with DMARDs : methotrexate (n=11), leflunomid (n=1), plaquenil (n=1), mycophenolate mofetil (n=2), Azathioprine (n=1). Seven patients received biologics because of refractory arthritis, including rituximab (n=4), infliximab (n=3), adalimumab (n=1), etanercept (1), tocilizumab (n=1) and/or abatacept (n=1). Other treatments were intraveinous immunoglobulins (n=1) and cyclophosphamide (n=1). Conclusions In ASS, ACPA are associated with severe and erosive arthritis, whereas the prognosis of the other specific ASS involvements seems good. Disclosure of Interest: None Declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkMFO3DAQhq2qlbosfQdLXAmdiRMnESe0BUqFSkULSL1YtjMpTneTxXaqcuPSF-2T4GUR6rUnj3___4znY2wP4QBRyPd6GPwtTavWhSwHFBlNS-0PsIT6FZthIeskS3jNZgAgsqKR1Vu2E0KfrlBjPWP9yeUZiBr_Pvz5MHk3_OB6iC7cD_GWog7EU9n6cUX7Tw-ZddFPy6UbdKSWr2kdXUuBa09c85X2P8nzseOBflGS-tENkaffUWq1y950ehno3fM5Z1cnx98WH7Pzi9OzxdF5ZlCWkDWAdVNiWbS2ynPZGOhqk0q0RnTW2g4KbRuw1uikCZO3BLZGI3IJBkUp5mxv23ftx7uJQlT9OPkhjVRYVVWD-QbGnB1uXdaPIXjq1Nq7tMC9QlAbuOofuGoDVz3BVRu4KZ1t0y5E-v0STfsrWYmqVJ-vF-rrp8UXuCy-q5vkl1u_WfX_NegRy1OW1w</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Meyer, A.</creator><creator>Lefevre, G.</creator><creator>Tournadre, A.</creator><creator>Le Goff, B.</creator><creator>Ottaviani, S.</creator><creator>Buchdahl, A.-L.</creator><creator>De Brandt, M.</creator><creator>Coquerelle, P.</creator><creator>Flipo, R.-M.</creator><creator>Falgarone, G.</creator><creator>Bernard, G.</creator><creator>Amoura, Z.</creator><creator>Benveniste, O.</creator><creator>Sibilia, J.</creator><creator>Hachulla, E.</creator><creator>Hervier, B.</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>201306</creationdate><title>FRI0381 During antisynthetase syndrome, anti-citrullinated peptides are a marker of severe joint disease</title><author>Meyer, A. ; Lefevre, G. ; Tournadre, A. ; Le Goff, B. ; Ottaviani, S. ; Buchdahl, A.-L. ; De Brandt, M. ; Coquerelle, P. ; Flipo, R.-M. ; Falgarone, G. ; Bernard, G. ; Amoura, Z. ; Benveniste, O. ; Sibilia, J. ; Hachulla, E. ; Hervier, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1650-901895154dc72269b0f8bc721cb3fcccf04ac90ccba21c3b2de0c81b3260b1353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meyer, A.</creatorcontrib><creatorcontrib>Lefevre, G.</creatorcontrib><creatorcontrib>Tournadre, A.</creatorcontrib><creatorcontrib>Le Goff, B.</creatorcontrib><creatorcontrib>Ottaviani, S.</creatorcontrib><creatorcontrib>Buchdahl, A.-L.</creatorcontrib><creatorcontrib>De Brandt, M.</creatorcontrib><creatorcontrib>Coquerelle, P.</creatorcontrib><creatorcontrib>Flipo, R.-M.</creatorcontrib><creatorcontrib>Falgarone, G.</creatorcontrib><creatorcontrib>Bernard, G.</creatorcontrib><creatorcontrib>Amoura, Z.</creatorcontrib><creatorcontrib>Benveniste, O.</creatorcontrib><creatorcontrib>Sibilia, J.</creatorcontrib><creatorcontrib>Hachulla, E.</creatorcontrib><creatorcontrib>Hervier, B.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meyer, A.</au><au>Lefevre, G.</au><au>Tournadre, A.</au><au>Le Goff, B.</au><au>Ottaviani, S.</au><au>Buchdahl, A.-L.</au><au>De Brandt, M.</au><au>Coquerelle, P.</au><au>Flipo, R.-M.</au><au>Falgarone, G.</au><au>Bernard, G.</au><au>Amoura, Z.</au><au>Benveniste, O.</au><au>Sibilia, J.</au><au>Hachulla, E.</au><au>Hervier, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FRI0381 During antisynthetase syndrome, anti-citrullinated peptides are a marker of severe joint disease</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2013-06</date><risdate>2013</risdate><volume>72</volume><issue>Suppl 3</issue><spage>A502</spage><epage>A502</epage><pages>A502-A502</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background The clinical meaning of anti-citrullinated peptide antibodies (ACPA) in antisynthetase syndrome (ASS) is unknown. Methods ASS patients with ACPA were identified among a 9 French center series of 284 patients with ASS and through declarative cases from clinicians registered on the Club Rhumatismes et Inflammation web site. ASS was defined by the presence of an antisynthetase antibody (ARS) and at least two organ involvements among interstitial lung disease (ILD) (abnormal pulmonary function tests and/or typical thoracic HRCT-scan), myositis (muscle weakness, CK level &gt;2 times normal range, myopathic changes on EMG and/or typical features on biopsy) and typical skin manifestations. ACPA were positive when &gt;30 IU/ml (ELISA and/or LUMINEX). Results Eleven female and two male (median age of 43 years, range 23-57) were tested positive for ACPA (median serum amount 183 IU/ml, range 33-7742). ARS were anti-Jo1 (n=10), anti-PL7 (n=2) or anti-PL12 (n=1) and were identified concomitantly (n=10), 4 years before (n=1) or 3-6 years after (n=2) the ACPA detection. Rheumatoid factor (latex) was found in 11 patients (213 IU/L, range 16-925). Among the tested patients, HLA-DR4 allele was found in one case. All patient suffered of symetrical arthritis, involving mainly small joints of the hand (n=13) sparing distal interphalangeal (IP) joints (n=12), with 9 tender joints (range 4-24) and 5.5 swollen joints (range 2-18). The visual analogic pain scale was 60/100, ranging from 20 to 66. Bone erosions were found in 10 patients (78%), mainly on metacarpophalangeal (n=6), metatarsophalangeal (n=4), wirst (n=4) and proximal IP (n=3) joints. All patients presented with at least 2 other symptoms of ASS: - ILD (n=11), occurring prior to (n=3, 2-5 years), at the same time of (n=4) or after (n=4, 1-6 years) the detection of ACPA, with variable severity (vital capacity 94% (range 44-100) and DLCO 67 % (range 48-103). HRCT findings were systematically in accordance with non-specific interstitial pneumonia. - Myositis (n=11) was diagnosed 5-11 years before (n=3), concomitantly (n=5) and 1-3 years after (n=3) the ACPA detection. Muscle weakness was present in 10 patients and the median CK level was 1807 UI/L (range 245-11,434). - Skin manifestations (n=9) were mechanic’s hand (n=3), signs of dermatomyositis (n=4) and/or Raynaud’s phenomenon (n=7) that appeared 1- 2 years before (n=3), concomitantly (n=3) or 3 years after (n=1) the detection of ACPA. All patients received corticosteroids while eleven were treated with DMARDs : methotrexate (n=11), leflunomid (n=1), plaquenil (n=1), mycophenolate mofetil (n=2), Azathioprine (n=1). Seven patients received biologics because of refractory arthritis, including rituximab (n=4), infliximab (n=3), adalimumab (n=1), etanercept (1), tocilizumab (n=1) and/or abatacept (n=1). Other treatments were intraveinous immunoglobulins (n=1) and cyclophosphamide (n=1). Conclusions In ASS, ACPA are associated with severe and erosive arthritis, whereas the prognosis of the other specific ASS involvements seems good. Disclosure of Interest: None Declared</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2013-eular.1508</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A502-A502
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1777912000
source BMJ Journals - NESLi2
title FRI0381 During antisynthetase syndrome, anti-citrullinated peptides are a marker of severe joint disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T17%3A25%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FRI0381%E2%80%85During%20antisynthetase%20syndrome,%20anti-citrullinated%20peptides%20are%20a%20marker%20of%20severe%20joint%20disease&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Meyer,%20A.&rft.date=2013-06&rft.volume=72&rft.issue=Suppl%203&rft.spage=A502&rft.epage=A502&rft.pages=A502-A502&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2013-eular.1508&rft_dat=%3Cproquest_cross%3E4008739481%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777912000&rft_id=info:pmid/&rfr_iscdi=true